MXCT Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.75 |
| 52 Week High | UK£4.30 |
| 52 Week Low | UK£2.31 |
| Beta | 1.13 |
| 11 Month Change | -6.14% |
| 3 Month Change | -23.61% |
| 1 Year Change | 12.24% |
| 33 Year Change | -64.92% |
| 5 Year Change | 155.81% |
| Change since IPO | 259.48% |
Recent News & Updates
Recent updates
MaxCyte, Inc. (LON:MXCT) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 09
Investors Appear Satisfied With MaxCyte, Inc.'s (LON:MXCT) Prospects As Shares Rocket 27%
May 30Analysts Are Upgrading MaxCyte, Inc. (LON:MXCT) After Its Latest Results
May 10Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Mar 14Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 07Analysts Have Just Cut Their MaxCyte, Inc. (LON:MXCT) Revenue Estimates By 22%
Oct 07Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Aug 12MaxCyte, Inc. (LON:MXCT) Analysts Just Slashed This Year's Revenue Estimates By 11%
May 15Investors Don't See Light At End Of MaxCyte, Inc.'s (LON:MXCT) Tunnel And Push Stock Down 28%
May 14We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Apr 27Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth
Nov 20Here's Why We're Not Too Worried About MaxCyte's (LON:MXCT) Cash Burn Situation
Mar 02We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Nov 17We're Not Worried About MaxCyte's (LON:MXCT) Cash Burn
Jul 25MaxCyte (LON:MXCT) Shareholders Have Enjoyed A Whopping 545% Share Price Gain
Feb 22Shareholder Returns
| MXCT | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -5.5% | 0.2% | -1.1% |
| 1Y | 12.2% | -19.9% | 10.2% |
Return vs Industry: MXCT exceeded the UK Life Sciences industry which returned -24.9% over the past year.
Return vs Market: MXCT exceeded the UK Market which returned 11.1% over the past year.
Price Volatility
| MXCT volatility | |
|---|---|
| MXCT Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 4.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MXCT has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: MXCT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MXCT fundamental statistics | |
|---|---|
| Market cap | UK£289.70m |
| Earnings (TTM) | -UK£27.32m |
| Revenue (TTM) | UK£35.03m |
8.3x
P/S Ratio-10.6x
P/E RatioIs MXCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MXCT income statement (TTM) | |
|---|---|
| Revenue | US$45.44m |
| Cost of Revenue | US$5.26m |
| Gross Profit | US$40.18m |
| Other Expenses | US$75.61m |
| Earnings | -US$35.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 88.43% |
| Net Profit Margin | -77.97% |
| Debt/Equity Ratio | 0% |
How did MXCT perform over the long term?
See historical performance and comparison